Satricabtagene autoleucel (satri-cel) as consolidation therapy following adjuvant treatment for locally advanced gastric or gastroesophageal junction cancer (G/GEJC): preliminary results from a phase Ib trial

Background

Results

Baseline Characteristics

Safety summary

Efficacy and Pharmacokinetics

Characteristics

Methods

Conclusion

Reference

E[(Char85t)0eris)8ti)3cs)]TJETBMC q0.00006 0CID 40BMC /Span <MMal]TJ1 0 (Primary endpoint was safety. Figure 2. CAR copies/µg DNA after infusion m0 g0 GS]TJET
Ean[(Char)2teristics